Bicoll in profit after three years Sino-German biotech Bicoll (Shanghai/Munich) has generated
its maiden after-tax profit in only its third year of operations. The firm, which specialises in high-tech natural product chemistry, has five strategic customers for its optimised small molecule libraries (known as Bilobac N) for drug discovery. Using its technology, including prediction toolbox Bipreselect,
Bicoll tests and develops its libraries for fees and milestone payments as well as working on in-house projects (BVV Vol 17, No 17, p13). This financial milestone places Bicoll “in a stable position from where we can target our second phase of growth to release the full potential of the company”, commented managing director Dr Kai Lamottke.